Press release
January 16, 2021
5 mins

Owkin Shares New AI-Severity Score for COVID-19 integrating CT Images Published to Nature Communications

COVID-19 vaccine distribution has begun across the globe, while many countries are still struggling with the rampant rise of infections. Owkin, a French-American startup pioneering AI and Federated Learning in medical research, has been focusing its COVID-19 research efforts on aspects of the pandemic that still require much public health attention, despite the arrival of an effective vaccine. Efforts to support frontline health systems as they devote their resources to the influx of COVID-19 related hospitalizations have resulted in the AI-Severity Score, published in Nature Communications this week.

This machine learning model, trained on multimodal data sets that include CT scans of the lungs (a routine procedure upon admission), is plug and play and able to predict the severity of a patient’s disease prognosis with a performance that surpasses all other currently published score benchmarks. The use of these scores supports hospital resource management and planning, a sometimes overlooked function that, when managed well, saves lives. This research was made possible through a consortium, called ScanCovIA, made up of Institut Gustave Roussy, Kremlin-Bicêtre APHP, Owkin, and Digital Vision Center of CentraleSupélec and INRIA.

Additionally, Owkin has been developing other machine learning models to discover more coronavirus epitopes that are most likely to be effective in future vaccines As the virus continues to mutate, we don’t yet know how long the current vaccines will remain efficacious or if, like the flu, they will require annual or semi-annual development. Furthermore, it may be possible to develop vaccines for genes within the virus’s DNA that are more stable, and less likely to mutate. Epitope prediction can speed vaccine development by narrowing the field of epitopes to test in the lab, and it can diversify our defences against the virus’s future mutations. Furthermore, these models can be deployed outside vaccine research; they can also be used in oncology research.

The ultimate aim of machine learning for epitope discovery is to have a better understanding of the immune response—these features of the model have their place across the spectrum of precision medicine research.

About Owkin

Owkin is the first full-stack TechBio company on a mission to understand complex biology and derive new multimodal biomarkers through AI.

We identify precision therapeutics, de-risk and accelerate clinical trials and develop diagnostics using AI trained on world-class patient data through privacy-enhancing technologies. We merge wet lab experiments with advanced AI techniques to create a powerful feedback loop for accelerated discovery and innovation in oncology, cardiovascular, immunity and inflammation.

Owkin also founded MOSAIC, the world’s largest spatial multi-omics atlas for cancer research across seven cancer indications.

Owkin has raised over $300 million through investments from leading biopharma companies, including Sanofi and BMS, and venture funds like Fidelity, GV and Bpifrance, among others.